We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AngioDynamics (ANGO) Shows Solid Results from RAPID Database
Read MoreHide Full Article
AngioDynamics, Inc. (ANGO - Free Report) recently announced the safety and efficiency outcomes from the Registry of AngioVac System Procedures In Detail (“RAPID”) database. The study proved that the AngioVac System was versatile, safe and effective for the removal of vascular thrombi and cardiac masses across a wide array of patient populations.
This should prove to be a breakthrough for the company’s Vascular Interventions and Therapies segment.
More on the Results
The registry was designed to study the patterns of use, safety and efficiency of the AngioVac System in the mass removal of unwanted intravascular material. The registry enrolled 234 patients across 21 sites, crossing its 200-patient enrollment goal. Out of all the enrolled patients, 48.3% had a mass in the right heart, 35.9% had caval thromboemboli, 8.5% had catheter-related thrombi, 1.7% had a pulmonary embolism and 5.6% had a combination of the above.
Notably, RAPID is the largest catheter-based thromboaspiration study completed till date.The encouraging results from the RAPID Registry confirm that the AngioVac System is ideal for use by a broad array of providers treating thrombus, clot and vegetations in both peripheral deep vein thrombosis and the right heart.
The primary goal of the registry was to capture data on the utilization of the AngioVac System for various anatomic locations. More than 70% of clot/mass elimination was achieved in a majority of the patient population.
The AngioVac System was successfully tested by a number of different medical practitioners, viz. cardiologists, electrophysiology cardiologists, cardiac surgeons, vascular surgeons and interventional radiologists. The wide range of providers, combined with the efficiency and safety results, highlights the unique and diverse nature of the AngioVac System.
Notable Developments
In September 2020, the company launched the Auryon Atherectomy System, a newly developed path-breaking technology for the treatment of Peripheral Artery Disease (“PAD”), which includes Critical Limb Ischemia and In-Stent Restenosis (“ISR”). The Auryon Atherectomy System is the first laser atherectomy system to proficiently treat lesions of any type, length or location (above and below the knee), with minimal impact on vessel walls. This launch is expected to boost the company’s Vascular Interventions and Therapies segment.
In August 2020, the company announced the enrollment of the first patient in the PATHFINDER I: Post-Market Registry. It is a pilot study to assess the safety and efficiency of the Auryon Atherectomy System in the real-world treatment of de novo, re-stenotic and ISR lesions in infrainguinal arteries of patients suffering from PAD.
Market Prospects
Per a Medgadget report, the global PAD market was valued at approximately $2.96 billion in 2018 and is expected to register 6.92% CAGR over the forecast period of 2018-2025. Hence, these study results are well-timed.
Price Performance
Shares of the Zacks Rank #2 (Buy) stock have gained 35.8% in the past three months compared with the industry’s rally of 2.1%.
Other Stocks to Consider
Some other top-ranked stocks from the broader medical space include AlignTechnology (ALGN - Free Report) , DaVita (DVA - Free Report) and Thermo Fisher Scientific
Align Technology has a projected long-term earnings growth rate of 18.3%.
Thermo Fisher has an estimated long-term earnings growth rate of 18%.
DaVita has a projected long-term earnings growth rate of 18.3%.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Image: Bigstock
AngioDynamics (ANGO) Shows Solid Results from RAPID Database
AngioDynamics, Inc. (ANGO - Free Report) recently announced the safety and efficiency outcomes from the Registry of AngioVac System Procedures In Detail (“RAPID”) database. The study proved that the AngioVac System was versatile, safe and effective for the removal of vascular thrombi and cardiac masses across a wide array of patient populations.
This should prove to be a breakthrough for the company’s Vascular Interventions and Therapies segment.
More on the Results
The registry was designed to study the patterns of use, safety and efficiency of the AngioVac System in the mass removal of unwanted intravascular material. The registry enrolled 234 patients across 21 sites, crossing its 200-patient enrollment goal. Out of all the enrolled patients, 48.3% had a mass in the right heart, 35.9% had caval thromboemboli, 8.5% had catheter-related thrombi, 1.7% had a pulmonary embolism and 5.6% had a combination of the above.
Notably, RAPID is the largest catheter-based thromboaspiration study completed till date.The encouraging results from the RAPID Registry confirm that the AngioVac System is ideal for use by a broad array of providers treating thrombus, clot and vegetations in both peripheral deep vein thrombosis and the right heart.
The primary goal of the registry was to capture data on the utilization of the AngioVac System for various anatomic locations. More than 70% of clot/mass elimination was achieved in a majority of the patient population.
The AngioVac System was successfully tested by a number of different medical practitioners, viz. cardiologists, electrophysiology cardiologists, cardiac surgeons, vascular surgeons and interventional radiologists. The wide range of providers, combined with the efficiency and safety results, highlights the unique and diverse nature of the AngioVac System.
Notable Developments
In September 2020, the company launched the Auryon Atherectomy System, a newly developed path-breaking technology for the treatment of Peripheral Artery Disease (“PAD”), which includes Critical Limb Ischemia and In-Stent Restenosis (“ISR”). The Auryon Atherectomy System is the first laser atherectomy system to proficiently treat lesions of any type, length or location (above and below the knee), with minimal impact on vessel walls. This launch is expected to boost the company’s Vascular Interventions and Therapies segment.
In August 2020, the company announced the enrollment of the first patient in the PATHFINDER I: Post-Market Registry. It is a pilot study to assess the safety and efficiency of the Auryon Atherectomy System in the real-world treatment of de novo, re-stenotic and ISR lesions in infrainguinal arteries of patients suffering from PAD.
Market Prospects
Per a Medgadget report, the global PAD market was valued at approximately $2.96 billion in 2018 and is expected to register 6.92% CAGR over the forecast period of 2018-2025. Hence, these study results are well-timed.
Price Performance
Shares of the Zacks Rank #2 (Buy) stock have gained 35.8% in the past three months compared with the industry’s rally of 2.1%.
Other Stocks to Consider
Some other top-ranked stocks from the broader medical space include AlignTechnology (ALGN - Free Report) , DaVita (DVA - Free Report) and Thermo Fisher Scientific
(TMO - Free Report) , each carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Align Technology has a projected long-term earnings growth rate of 18.3%.
Thermo Fisher has an estimated long-term earnings growth rate of 18%.
DaVita has a projected long-term earnings growth rate of 18.3%.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>